Drug Profile
Afabicin - Debiopharm
Alternative Names: AFN 1720; AFN-1252-prodrug; Debio 1450; Debio-1452-prodrugLatest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator Affinium Pharmaceuticals
- Developer Debiopharm Group
- Class Anti-infectives; Benzofurans; Naphthyridines; Small molecules
- Mechanism of Action Enoyl-ACP reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bone and joint infections; Skin and soft tissue infections
- No development reported Staphylococcal infections
Most Recent Events
- 30 Sep 2022 Afabicin is still in phase II trials for Bone and joint infections in USA, Ukraine (IV)(PO) (NCT03723551)
- 16 Mar 2022 Afabicin - Debiopharm receives Orphan Drug status for Bone and joint infections in USA prior to March 2022 (Debiopharm pipeline, March 2022)
- 26 Feb 2019 Phase-II clinical trials in Bone and joint infections in Ukraine, USA (PO) (NCT03723551; 9261350)